All Modules
Infectious Diseases I
Ł Ų“Ų§ŁŲÆŲ© Ų§ŁŁŁŲÆŁŁ
Ų§ŲØŲÆŲ£ Ų§ŁŁŲ±Ų§Ų”Ų©
š¦
Module 06 • Infectious Diseases
Infectious Diseases I
VAP, CLABSI, Intra-abdominal & Skin Infections
Jacob Schwarz, Pharm.D., MBA, FAzPA, BCIDP, BCCCP, BCPS
Mayo Clinic, Phoenix, AZ
61
Total Pages
57
Content Pages
1
Quiz Pages
142
Min to Read
26K
Words
ŁŁŲÆŁŁ
All Pages
61 pages
All
Learning Objectives
Content
Tables
Self-Assessment
Answers
Abbreviations
1
Content
1 min
Infectious Diseases I Jacob Schwarz, Pharm.D., MBA, FAzPA, BCIDP, BCCCP, BCPS Mayo Clinic Phoenix, AZā¦
2
Content
1 min
Infectious Diseases I Infectious Diseases I Jacob Schwarz, Pharm.D., MBA, FAzPA, BCIDP, BCCCP, BCPS Mayo Clinic Phoenix, AZā¦
3
Learning Objectives
3 min
Infectious Diseases I Learning Objectives 1. Develop risk factorābased empiric antibiotic regi- mens for patients with suspected ventilator-associated pneumonia. 2. Develop empiric and definitive aā¦
4
Content
4 min
Infectious Diseases I 2. Based on the 2016 IDSA guidelines, which empiric antibiotic regimen is best for the likely causative pathogen(s) of K.P.ās suspected VAP? A. Azithromycin plus moxifloxacinā¦
5
Content
3 min
Infectious Diseases I 8. J.E. is a 67-year-old woman admitted to the MICU for severe metabolic acidosis secondary to uninten- tional metformin overdosage. Her ICU stay has been complicated by a femā¦
6
Exam Content Outline
1 min
Infectious Diseases I BPS Critical Care Pharmacy Examination Content Outline This chapter covers the following sections of the Critical Care Pharmacy Examination Content Outline: 1. Domain 1: Criticaā¦
7
Content
3 min
Infectious Diseases I I.ā VENTILATOR-ASSOCIATED PNEUMONIA A. Epidemiology 1. About 90% of hospital-acquired pneumonia episodes in critically ill patients occur during MV. MV is an independent riskā¦
8
Content
3 min
Infectious Diseases I i. Preferentially use multimodal strategies and medications other than benzodiazepines to manage agitation. ii. Use a protocol to minimize sedation. iii. Implement a ventilatā¦
9
Content
3 min
Infectious Diseases I a. If an invasive strategy with quantitative cultures is used, it is suggested that antibiotics be withheld rather than continued if quantitative culture results are below theā¦
10
Data Tables
2 min
Infectious Diseases I Table 1. VAP Classifications and Recommended Empiric Antibiotic Therapy Based on 2016 IDSA VAP Guidelines Likely Pathogens Recommended Empiric Antibiotic(s)a Patients without MDRā¦
11
Content
3 min
Infectious Diseases I 4. Definitive antibiotic therapy should be focused on the causative pathogen(s) identified on lower respiratory tract culture. a. Pathogen-specific definitive antibiotic choicā¦
12
Data Tables
3 min
Infectious Diseases I (c) The rate of MDR pathogens during a recurrent VAP episode was higher in patients in the 15-day group. ii. Two meta-analyses that included the results of the PneumA trial suā¦
13
Data Tables
3 min
Infectious Diseases I Characteristic 2005 Guidelines 2016 Guidelines Classification Early onset or late onset No longer differentiate VAP episodes based on time from hospital admission Emphasis on lā¦
14
Content
3 min
Infectious Diseases I Patient Cases 1. C.T. is a 48-year-old man sustaining a 40% total body surface area burn to his left side with likely inhala- tional injury requiring mechanical ventilation. C.Tā¦
15
Content
4 min
Infectious Diseases I B. Diagnosis 1. Clinical signs and symptoms of infection have poor sensitivity and specificity. Fever is the most sensitive clinical finding, whereas inflammation or purulenceā¦
16
Content
3 min
Infectious Diseases I b. Complicated CLABSI i. Endocarditis; immunosuppression (S. aureus only); diabetes (S. aureus only); chronic intravascular hardware; osteomyelitis; positive blood cultures grā¦
17
Content
3 min
Infectious Diseases I Patient Cases (continued) Questions 5 and 6 pertain to the following case. F.P. is a 29-year-old man admitted to the MICU from another hospital with severe, alcohol-induced, sterā¦
18
Content
3 min
Infectious Diseases I C. Treatment 1. A urinary culture should be obtained before initiation of antimicrobial therapy. 2. If an indwelling catheter has been in place for longer than 2 weeks, the caā¦
19
Content
3 min
Infectious Diseases I IV.ā COMPLICATED INTRA-ABDOMINAL INFECTION A. Epidemiology 1. Complicated intra-abdominal infection spans prehospital and in-hospital dispositions and a variety of pathogenicā¦
20
Content
3 min
Infectious Diseases I a. Esophageal, gastric, and duodenal secretions are usually sterile or with limited inocula of gram- positive bacteria and Candida spp. b. Proximal small bowel is densely populā¦
21
Content
3 min
Infectious Diseases I c. Community-acquired, mild to moderate severity, low risk for treatment failure i. Routine culture is not recommended. ii. Empiric antibiotic therapy should include agents acā¦
22
Content
2 min
Infectious Diseases I iii. Anti-enterococcal therapy should be considered in patients with recent exposure to broad- spectrum antimicrobial therapy, septic shock, postoperative infections, and thoseā¦
23
Content
2 min
Infectious Diseases I Patient Cases 9. D.L. is a 69-year-old woman admitted from home to the SICU with severe acute abdominal pain in the left lower quadrant. An abdominal CT reveals free air in theā¦
24
Content
3 min
Infectious Diseases I 2. About 20% ā30% of acute pancreatitis episodes are severe, have evidence of pancreatic necrosis, and are associated with local and systemic complications (e.g., multiple orgaā¦
25
Content
3 min
Infectious Diseases I 5. Additional late complications of peripancreatic necrosis include secondary pancreatic infection of previously acute necrotic collections during the first 4 weeks after preseā¦
26
Content
3 min
Infectious Diseases I v. If infection is confirmed, antibiotic therapy should be de-escalated toward the identified pathogen(s) according to antibiotic susceptibility. vi. Definitive antibiotic theā¦
27
Content
3 min
Infectious Diseases I 2. C. difficile is transmitted person to person through the fecal-oral route. The capability to become dormant in spores increases the potential for environmental spread. 3. Cā¦
28
Content
3 min
Infectious Diseases I C. Risk Factors 1. Antibiotic therapy is the most important risk factor. a. All antibiotic classes have been associated with CDI. b. Highest-risk (listed by decreasing risk)ā¦
29
Content
4 min
Infectious Diseases I c. Enzyme immunoassay (EIA) tests for C. difficile toxins A and B are rapid and widely available; however, poor sensitivity may limit their utility. Obtaining serial samples haā¦
30
Content
2 min
Infectious Diseases I iii. Metronidazole is primarily only recommended in addition to oral vancomycin for the treatment of severe-complicated/fulminant CDI. The IDSA guidelines indicate that metroniā¦
31
Data Tables
2 min
Infectious Diseases I Table 3. Treatment Options for Clostridioides difficile Infection Clinical Definition ACG 2013 IDSA/SHEA 2018 IDSA/SHEA 2021 Focused Update ACG 2021 Initial episode, nonsevā¦
32
Data Tables
2 min
Infectious Diseases I Clinical Definition ACG 2013 IDSA/SHEA 2018 IDSA/SHEA 2021 Focused Update ACG 2021 First recurrence Same regimen as used for initial episode, unless severe; if severe,ā¦
33
Data Tables
2 min
Infectious Diseases I Clinical Definition ACG 2013 IDSA/SHEA 2018 IDSA/SHEA 2021 Focused Update ACG 2021 Second recurrence Vancomycin PO, then 28-day dosage taper Vancomycin in tapered andā¦
34
Content
3 min
Infectious Diseases I Patient Cases 14. K.L. is a 57-year-old man admitted to the MICU with diffuse abdominal pain, temperature 101.9Ā°F (38.8Ā°C), WBC 27 x 103 cells/mm3, heart rate 125 beats/minute,ā¦
35
Content
3 min
Infectious Diseases I VII.ā WOUND INFECTION A. The epidemiology, definitions, etiology, and prevention for postoperative wound infections are discussed in the Infectious Diseases II chapter. B. Diaā¦
36
Content
3 min
Infectious Diseases I b. Antibiotic therapy is empiric or definitive. i. Empiric antibiotic therapy should be initiated as early as possible. ii. Polymicrobial infection should be suspected, with eā¦
37
Content
4 min
Infectious Diseases I VIII.ā INFLUENZA A. Epidemiology 1. Influenza is a seasonal viral illness affecting all ages and associated with significant morbidity and mortality. Seasonal patterns in theā¦
38
Content
3 min
Infectious Diseases I 3. Institutions should begin implementing influenza screening and infection control measures when influenza viruses are confirmed to be in the local community. 4. The CDC recoā¦
39
Content
3 min
Infectious Diseases I c. Neuraminidase inhibitors continue to be the mainstay of antiviral therapy for recent influenza A and B strains. These agents inhibit viral neuraminidase, decreasing the releā¦
40
Data Tables
2 min
Infectious Diseases I ii. High levels of resistance to the adamantanes (amantadine and rimantadine) have persisted among circulating influenza A viruses. The adamantanes are not effective against inā¦
41
Data Tables
2 min
Infectious Diseases I Agent Influenza Activity Bioavailability Half-life (hr) Treatment Dosage Adverse Effects Comments Zanamivir Neuraminidase inhibitor; A and B Inhaled: Up to 17% 2.5ā5 10 mā¦
42
Content
3 min
Infectious Diseases I Patient Cases 19. T.Y., a 32-year-old woman who has had flulike symptoms for the past 72 hours, presents to the ED from home with severe fatigue, shortness of breath, and rigorā¦
43
Content
3 min
Infectious Diseases I 6. Risk factors for COVID-19ārelated hospitalization span several comorbidities, including hypertension, diabetes, cardiovascular disease, COPD, obesity, and chronic kidney disā¦
44
Content
3 min
Infectious Diseases I 4. The incubation period for SARS-CoV-2 is estimated to be up to 14 days from exposure. Information on onset and duration of viral shedding and infectious potential is still emā¦
45
Content
3 min
Infectious Diseases I ii. Fluid resuscitation: Conservative management strategy using balanced crystalloid solutions iii. Vasopressors: Norepinephrine as first line; vasopressin or epinephrine as seā¦
46
Content
3 min
Infectious Diseases I (1) The COVACTA trial (N Engl J Med 2021;384:1503-16) was a randomized, placebo- controlled trial in 438 hospitalized adults with severe COVID-19 pneumonia. (A) Patients wereā¦
47
Content
3 min
Infectious Diseases I (A) At enrollment, 32% of patients had severe disease, with 10.7% of patients requiring MV or ECMO. Patients receiving corticosteroids for COVID-19 were excluded. (B) Overallā¦
48
Content
3 min
Infectious Diseases I (3) AntiāIL-6 monoclonal antibody siltuximab (4) Bruton tyrosine kinase inhibitors (e.g., acalabrutinib, ibrutinib, zanubrutinib) e. Antiviral therapy i. Remdesivir (a) Nuclā¦
49
Data Tables
2 min
Infectious Diseases I ii. Hydroxychloroquine or chloroquine (a) Antimalarial agents that, in vitro, increase the endosomal pH, inhibiting fusion of SARS- CoV-2 to the host cell membranes (b) Not reā¦
50
Data Tables
3 min
Infectious Diseases I Disease Severity Remdesivir Dexamethasonea Baricitinib Tocilizumabb Anticoagulation High-flow oxygen device or noninvasive ventilation requirement Recommended in combinatiā¦
51
Content
3 min
Infectious Diseases I REFERENCES Ventilator-Associated Pneumonia BouglĆ© A, Tuffet S, Federici L, et al. Comparison of 8 versus 15 days of antibiotic therapy for Pseudomonas aeruginosa ventilator-assā¦
52
Content
3 min
Infectious Diseases I infections in the ICU. N Engl J Med. 2006;355(26):2725- 2732. https://doi.org/10.1056/nejmoa061115 Catheter-Associated Urinary Tract Infections Centers for Disease Control and Prā¦
53
Content
3 min
Infectious Diseases I Dellinger EP, Tellado JM, Soto NE, et al. Early antibiotic treatment for severe acute necrotizing pancreatitis: a ran- domized, double-blind, placebo-controlled study. Ann Surgā¦
54
Content
3 min
Infectious Diseases I Wound Infection Anaya DA, Dellinger EP. Necrotizing soft-tissue infec- tion: diagnosis and management. Clin Infect Dis. 2007;44(5):705-710. https://doi.org/10.1086/511638 Calderā¦
55
Content
2 min
Infectious Diseases I Kalil AC, Patterson TF, Mehta AK, et al. Baricitinib plus remdesivir for hospitalized adults with Covid-19. N Engl J Med. 2021;384(9):795-807. https://doi.org/10.1056/ nejmoa20ā¦
56
Answers & Explanations
4 min
Infectious Diseases I ANSWERS AND EXPLANATIONS TO PATIENT CASES 1. Answer: A The patient has suspicion for MDR VAP, as evidenced by the presence of clinical signs of infection, the patientās increaā¦
57
Content
4 min
Infectious Diseases I antibiotic therapy should be considered if there is strong clinical suspicion for infection (Answer C is correct). Waiting for final culture results before initiating antimi- cā¦
58
Content
4 min
Infectious Diseases I gram-negative bacilli and yeast (Answer A is incorrect). Empiric antimicrobial therapy is indicated for suspected infected pancreatitis. Extended-spectrum carbapenems, which aā¦
59
Content
2 min
Infectious Diseases I 19. Answer: D This patient likely has severe influenza amid a local seasonal outbreak. Local infection patterns suggest a prevalence of influenza A and B strains. Empiric infā¦
60
Self-Assessment
4 min
Infectious Diseases I ANSWERS AND EXPLANATIONS TO SELF-ASSESSMENT QUESTIONS 1. Answer: D The patient described has early onset VAP without apparent updated risk factors for MDROs (Answers A, B, andā¦
61
Content
3 min
Infectious Diseases I and guideline recommendations do not support prophy- lactic antibiotic therapy for preventing infection of the necrotic tissue (Answer D is incorrect). The mainstay of therapyā¦
No pages match your search
Infectious Diseases I
Module 6 • 61 pages
Begin Module
Total pages
61
Reading time
~142 min
Category
Infectious Diseases
Quick Navigation
Jump to a section
Content
Page 1
Learning Objectives
Page 3
Content
Page 4
Exam Content Outline
Page 6
Content
Page 7
Data Tables
Page 10
Content
Page 11
Data Tables
Page 12
All 20 Modules
Navigate the course
ā
View all modules
Previous Module
Module 5
Next Module
Module 7